Over four decades of innovation have transformed HIV into a manageable chronic condition through advances in ART and PrEP. Yet unmet needs persist, particularly for vulnerable populations, as drug resistance and funding challenges emerge. This IQVIA Institute report examines global HIV R&D trends, spending dynamics, and policy pressures, highlighting the need for sustained investment and collaboration to ensure continued innovation and equitable access to care.
Efforts to strengthen Europe as a global center for oncology clinical trials have been underway for some time, and multiple initiatives have been launched by stakeholders in recent years. At the same time, changes at the U.S. FDA and implementation of the EU Health Technology Assessment Regulation from January 2025 are bringing new considerations for sponsors deciding where to place their trial sites.
During this symposium, we will assess what progress has been achieved since the IQVIA Institute’s symposium held a year ago, examine the changes brought by the new U.S. administration, and discuss the impact of Joint Clinical Assessment requirements for all new oncology drugs submitted for registration by the EMA. We will also explore the increased use of trial sites in China and Australia.
Learn about spending and usage of medicines in the past year and outlook to the future, globally and across specific therapy areas and countries.
Discover trends in drug approvals and launches, pipeline activity, and data on clinical trial activity.
Examine the state of the U.S. health system, medicine usage, drug pricing, and costs for patients.
Explore research and development in oncology and the progress being made to improve representativeness of race and ethnicity in clinical trial populations.